A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
Introduction: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentat...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Regenerative Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352320419301294 |
id |
doaj-98248da26c8e412f9bfdaa5afafee6a9 |
---|---|
record_format |
Article |
spelling |
doaj-98248da26c8e412f9bfdaa5afafee6a92020-11-25T02:23:35ZengElsevierRegenerative Therapy2352-32042020-06-011495102A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cellsYasutaka Fujita0Masuhiro Nishimura1Natsuki Watanabe Komori2Tamaki Wada3Chikage Shirakawa4Taichi Takenawa5Osamu Sawamoto6Masako Doi7Corresponding author. Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Tokushima, 772-8601, Japan. Fax: +81 88 684 2421.; Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanIntroduction: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. Methods: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. Results: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. Discussion: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use.http://www.sciencedirect.com/science/article/pii/S2352320419301294Cell preservation solutionDextran 40Human adipose-derived mesenchymal stromal cellsTrehalose |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yasutaka Fujita Masuhiro Nishimura Natsuki Watanabe Komori Tamaki Wada Chikage Shirakawa Taichi Takenawa Osamu Sawamoto Masako Doi |
spellingShingle |
Yasutaka Fujita Masuhiro Nishimura Natsuki Watanabe Komori Tamaki Wada Chikage Shirakawa Taichi Takenawa Osamu Sawamoto Masako Doi A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells Regenerative Therapy Cell preservation solution Dextran 40 Human adipose-derived mesenchymal stromal cells Trehalose |
author_facet |
Yasutaka Fujita Masuhiro Nishimura Natsuki Watanabe Komori Tamaki Wada Chikage Shirakawa Taichi Takenawa Osamu Sawamoto Masako Doi |
author_sort |
Yasutaka Fujita |
title |
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_short |
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_full |
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_fullStr |
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_full_unstemmed |
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_sort |
pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
publisher |
Elsevier |
series |
Regenerative Therapy |
issn |
2352-3204 |
publishDate |
2020-06-01 |
description |
Introduction: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. Methods: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. Results: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. Discussion: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use. |
topic |
Cell preservation solution Dextran 40 Human adipose-derived mesenchymal stromal cells Trehalose |
url |
http://www.sciencedirect.com/science/article/pii/S2352320419301294 |
work_keys_str_mv |
AT yasutakafujita apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT masuhironishimura apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT natsukiwatanabekomori apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT tamakiwada apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT chikageshirakawa apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT taichitakenawa apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT osamusawamoto apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT masakodoi apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT yasutakafujita pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT masuhironishimura pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT natsukiwatanabekomori pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT tamakiwada pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT chikageshirakawa pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT taichitakenawa pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT osamusawamoto pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT masakodoi pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells |
_version_ |
1724858651972206592 |